Table 3.
Sexual adverse events associated with drugs used in the treatment for BPH–LUTS reported from clinical trials (Adapted from Refs (50,52))
| ED (%) | EJD (%) | Retrograde ejaculation*(%) | Decreased libido (%) | |
|---|---|---|---|---|
| Alpha-blockers | ||||
| Alfuzosin | 3 | – | 1 | |
| Doxazosin | 4 | 0 | 3 | |
| Tamsulosin | 4 | 10 | 2.1* | – |
| Terazosin | 5 | 1 | 3 | |
| Placebo | 4 | 1 | 1.1* | 3 |
| Silodosin | – | 28† | 14.2* | – |
| Dutasteride‡ | ||||
| Dutasteride | 7.3 | 2.2 | 4.2 | |
| Placebo | 4.0 | 0.8 | 2.1 | |
| Finasteride‡ | ||||
| Finasteride§ | 8.1 | 4.5 | 6.4 | |
| Placebo§ | 3.7 | 0.9 | 3.4 | |
*
Taken from Chapple (52).
†
Treatment-emergent adverse events. Data from pooled results of two phase III, 12-week studies.
‡
Drug-related adverse events reported in year 1 of study.
§
EJD includes decreased ejaculate volume and ejaculation disorder; ED reported as ‘impotence’. ED, erectile dysfunction; EJD, ejaculatory dysfunction; retrograde ejaculation, orgasm with no semen, orgasm semen quantity reduced, and retrograde ejaculation.